Clinical development of advanced therapy medicinal products in Europe: Evidence that regulators must be proactive

Molecular Therapy

Volumn 20, Issue 3, 2012, Pages 479-482

  MacIulaitis, Romaldas ^a,b   D'Apote, Lucia ^a   Buchanan, Andrew ^a   Pioppo, Laura ^a,c   Schneider, Christian K ^a,d,e  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^c UNIVERSITY OF PALERMO   (Italy)

^d DANISH MEDICINES AGENCY   (Denmark)

^e INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL AND TISSUE EXTRACTS;

ADVANCED THERAPY MEDICINAL PRODUCT; CARDIOVASCULAR DISEASE; CELL BASED MEDICINAL PRODUCT; CELL DIFFERENTIATION; CELL THERAPY; DATA BASE; DENDRITIC CELL; EUROPE; FUNDING; GENE THERAPY; GENE THERAPY MEDICINAL PRODUCT; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; LEGAL ASPECT; MELANOMA; MESENCHYMAL STEM CELL; NOTE; RARE DISEASE; REGISTER; SOLID TUMOR; SOMATIC CELL; SOMATIC CELL THERAPY MEDICINAL PRODUCT; TISSUE ENGINEERED PRODUCT; TREATMENT INDICATION; VALIDATION PROCESS;

EID: 84857756807     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.13     Document Type: Note

References (18)

1. European Commission (2009). Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products. Official Journal of the European Union 15.9.2009. L242/3-12.
2. European Parliament and Council (2007). Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union 10.12.2007. L324/121-137.
3. European Medicines Agency (2012). Certification procedure for SMEs 〈http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/ general-content-000300.jsp&mid=WC0b01ac058007f4bd〉.
4. European Medicines Agency (2012). Scientific advice and protocol assistance 〈http://www.ema.europa. eu/ema/index.jsp?curl=pages/regulation/ general/general-content-000049.jsp&mid=WC0b01ac058002 29b9&jsenabled= true〉.
5. Schneider, CK and Schäffner-Dallmann, G (2008). Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nat Rev Drug Discov 7: 893-899.
6. Committee for Advanced Therapies (CAT); CAT Scientific Secretariat, Schneider, CK, Salmikangas, P, Jilma, B, Flamion, B, Todorova, LR, Paphitou, A et al. (2010). Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 9: 195-201.
7. European Commission (2001). Commission Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Union 1.5.2001. L121/34-44.
8. Sanzenbacher, R, Dwenger, A, Schuessler-Lenz, M, Cichutek, K and Flory, E (2007). European regulation tackles tissue engineering. Nat Biotechnol 25: 1089-1091. (Pubitemid 47538102)
9. Committee for Advanced Therapies (CAT) and CAT Scientific Secretariat (2010). Use of unregulated stemcell based medicinal products. Lancet 376: 514.
10. Debey, S, Schoenbeck, U, Hellmich, M, Gathof, BS, Pillai, R, Zander, T et al. (2004). Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J 4: 193-207. (Pubitemid 38786558)
11. European Medicines Agency (2010). Committee for Advanced Therapies (CAT) Work Programme 2010-2015 〈http://www.ema.europa.eu/docs/en-GB/document- library/Work-programme/2010/11/WC500099029.pdf〉.
12. Regnstrom, J, Koenig, F, Aronsson, B, Reimer, T, Svendsen, K, Tsigkos, S et al. (2010). Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur J Clin Pharmacol 66: 39-48.
13. Baker, M (2011). Stem-cell pioneer bows out. Nature 479: 459.
14. Geron (2011). News release: Geron to focus on its novel cancer programs 〈http://www.reuters. com/article/2011/11/14/idUS242102+14-Nov- 2011+BW20111114〉.
15. European Medicines Agency (2006). Mandate of the EMEA Innovation Task Force (ITF) EMEA/20220/06 〈http://www.ema.europa.eu/docs/en-GB/document- library/Other/2009/10/WC500004912.pdf〉.
16. European Medicines Agency (2012). ATMP classification 〈http://www.ema.europa.eu/ema/index. jsp?curl=pages/regulation/general/ general-content-000296.jsp&mid=WC0b01ac058007f4bc〉 (2012).
17. European Medicines Agency (2011). Report from CAT-Interested Parties Focus Groups (CAT-IPs FG) on non-clinical development of ATMPs EMA/CAT/134694/2011 〈http://www.ema.europa.eu/docs/en-GB/document-library/ Report/2011/03/WC500103895.pdf〉.
18. European Medicines Agency and European Society for Gene and Cell Therapy (ESGCT) (2011). Conference Programme CAT-ESGCT Satellite Workshop: Advanced therapy medicinal products: from promise to reality. Regulatory path for translation of research to commercial medicinal products 〈http://www.esgct. eu/resources/pdf/congress/2011/programme-EMA-CAT. pdf〉